Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
Status:
Completed
Trial end date:
2015-01-28
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in
patients when compared to placebo (a tablet that does not contain active product) and when
compared to a marketed product containing pregabalin (Lyrica®). Furthermore, this trial will
be undertaken to find out if the patient's general health and well-being improves under trial
treatment.
The concentrations of cebranopadol in the blood will be investigated to get a better
understanding of how it is absorbed from the gut, distributed and broken down in the body,
and eliminated from the body.